What mAbsolve does

mAbsolve is a privately held Oxford-based biotechnology company founded in December 2019 as a spin-out from Absolute Antibody. The company develops and licenses the STR (Silently Turned off Receptor) Fc silencing technology, a defined combination of three point mutations — L234, L235, and G236R — in the CH2 domain of the immunoglobulin Fc region. The technology eliminates detectable binding to Fc gamma receptors and C1q without adverse effects on manufacturability, stability, FcRn binding, or immunogenicity, and is positioned as a comprehensive improvement over incumbent approaches such as LALA, LALAPG, and aglycosylated variants. mAbsolve estimates that for approximately 50% of antibody and Fc fusion proteins in clinical development, Fc effector function is not the intended mechanism of action, and in those cases STR addresses a meaningful safety and efficacy risk.

The company operates a non-exclusive technology licensing business model and does not develop its own therapeutic candidates. Licenses are offered on affordable terms with success-based milestone payments and no royalties, and are structured to be accessible to biotech companies of all sizes, CROs, academic institutions, and regulatory bodies. Distribution is amplified through channel partners such as Absolute Antibody, evitria, GenScript ProBio, Antibody Analytics, and Antibody Solutions, which embed STR into their antibody discovery and expression services. mAbsolve also operates the INN Analysis Database, cataloging over 800 antibody-based biologics with WHO INN designations, and has published peer-reviewed work analyzing over 70 Fc silencing variants.

As of late 2025, two commercial STR licensees had advanced into clinical trials, and granted patents cover STR mutations in the United States, United Kingdom, Canada, Australia, and Japan, with divisional protection extending to nucleic acids and Fc fusion proteins. The leadership team is anchored by founders with deep credentials in therapeutic antibody development, including Prof. Geoff Hale (CEO) and Dr. Ian Wilkinson (CSO), the inventor of STR.

Name

mAbsolve

Legal name

mAbsolve Limited

Website

https://mabsolve.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

mAbsolve is an Oxford-based biotech that licenses STR Fc silencing mutations to therapeutic antibody developers, enabling safer biologics by eliminating unwanted Fc receptor and C1q binding without compromising stability or half-life.

Ownership category

akta.pro rank

Product category

Biotechnology Research Tools / Therapeutic Antibody Engineering

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industry

Fusion Proteins & Fc-Engineered Biologics (HLAAAAAD)

Keywords

• Therapeutic antibody engineering
• Fc silencing technology
• Antibody licensing platform
• Biologics research tools
• Fc receptor binding assays

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technology Licensing: mAbsolve generates revenue through licensing its STR Fc silencing technology. Non-exclusive research and commercial licenses are available on affordable terms. Payments are based on success-based milestones with no royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

mAbsolve develops and out-licenses STR (Silently Turned off Receptor), a proprietary Fc silencing technology consisting of three mutations in the CH2 domain of antibody Fc regions that eliminates binding to all Fc gamma receptors and C1q. The company licenses STR on non-exclusive research and commercial terms to biotech, pharma, contract research organizations, and academic institutions developing therapeutic antibodies and Fc fusion proteins where Fc effector function is not the desired mechanism of action. Revenue is generated through success-based milestone payments with no royalties, complemented by an INN Analysis Database resource covering over 800 antibody-based biologics.

Product overview

mAbsolve is a biotechnology company offering the STR (Silence Technology Research) Fc silencing platform - a novel set of truly silent Fc mutations for therapeutic antibody and Fc fusion protein development. The core product is the STR Technology itself, which consists of a novel combination of three mutations in the CH2 domain that completely eliminate Fc receptor and C1q binding. The company also provides an INN Analysis Database containing detailed information on over 800 antibody-based biologics. mAbsolve licenses its technology widely on non-exclusive terms with success-based milestones and no royalties, targeting organizations developing antibodies where effector function is not the mechanism of action.

Differentiator

Problem solved

Functional benefit

Products and services

• STR (Silently Turned off Receptor) Fc Silencing Technology A proprietary set of three mutations (L234A, L235A combined with G236R) in the CH2 domain of the antibody Fc region that eliminates binding to all Fc gamma receptors and C1q without adverse effects on manufacturability, stability, FcRn binding, or immunogenicity. Licensed to therapeutic antibody and Fc fusion protein developers.
• INN Analysis Database A searchable reference resource cataloging over 800 antibody-based biologics with registered WHO International Non-Proprietary Names, providing data on primary amino acid sequence, design format, isotype, subtype, allotype, and Fc mutations including silencing approaches.
• STR Fc Silencing Technology Licensing Program Non-exclusive research and commercial licenses for STR technology with success-based milestone payments and no royalties, designed for organizations developing therapeutic antibodies or Fc fusion proteins where Fc effector function is not the desired mechanism of action.

Quantifiable outcome

• No detectable binding to Fc gamma receptors or C1q in SPR, cell-based reporter assays, and cytokine release assays with human PBMCs
• +2 more outcomes

Named customers11 records

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

20 partnerships are on record, tiered minor and core.

• UMass Chan Medical School (NHPRR)minorOEM/ Whitelabel/ Licensing Partner · 22 August 2024Nonhuman Primate Reagent Resource licenses STR technology for reagent development.
• Antibody SolutionsminorOEM/ Whitelabel/ Licensing Partner · 5 December 2023License to provide clients with access to STR technology during discovery campaigns.
• MHRA (NIBSC)coreOEM/ Whitelabel/ Licensing Partner · 12 June 2023Medical and Healthcare products Regulatory Agency licenses STR technology to produce gold standard negative controls for Fc receptor binding assays.
• OmniAbcoreOEM/ Whitelabel/ Licensing Partner · 23 February 2023Exclusive, sublicensable access to STR technology for antibodies generated using OmniAb's antibody discovery platform. Major platform licensing deal expanding technology availability.
• GenScript ProBiocoreOEM/ Whitelabel/ Licensing Partner · 28 November 2022License enabling GenScript ProBio's worldwide client base to access STR technology in early research phases of antibody development projects.
• ScancellminorOEM/ Whitelabel/ Licensing Partner · 23 June 2022UK-based company developing anti-glycan antibodies licenses STR for evaluation in their therapeutic antibody pipeline.
• Antibody AnalyticscoreOEM/ Whitelabel/ Licensing Partner · 6 June 2022License for use as true negative controls in Fc receptor or C1q based assays. Provides gold-standard negative control for comparison in effector function characterization assays.
• NovalgenminorOEM/ Whitelabel/ Licensing Partner · 19 October 2020License for evaluation in pipeline of therapeutic antibodies for treatment of cancer, leukemias, and cardiovascular disease.
• ONA TherapeuticsminorOEM/ Whitelabel/ Licensing Partner · 9 October 2020License for evaluation in pipeline of therapeutic antibodies for advanced cancer.
• Absolute AntibodycoreStrategic or Co-development PartnerAbsolute Antibody licenses STR technology to offer clients easy license-free access to the STR Fc silencing platform for antibody research and development. Absolute Antibody also provides custom services for antibody engineering, sequencing, humanization, and expression.
• CelentyxminorStrategic or Co-development PartnerContract Research Organisation providing immunology services using patient and donor tissues and cells. Offers bespoke assay services in immuno-oncology, autoimmunity, inflammation, fibrosis, and neuroinflammation.
• evitriacoreChannel Partner/ Reseller/ Distributorevitria licenses STR technology to supply global client base with antibodies bearing STR silencing modifications. Market-leading transient CHO expression service provider with track record of 90,000+ transfections.
• Sir William Dunn School of PathologyminorStrategic or Co-development PartnerWorld-famous research institution home to many mAbsolve founders including Herman Waldmann FRS. Site of development of penicillin and cephalosporin.
• Pivotal ScientificcoreImplementation/ SI/ Consulting PartnerInternational biotechnology consultancy managing mAbsolve's website and offering business planning, market analysis, web design, social media, brand design, B2B introductions, and networking opportunities.
• Protein StableminorStrategic or Co-development PartnerCollaborated with mAbsolve to publish comprehensive analysis of over 70 Fc silencing variants. Applies innovation in protein characterisation focusing on high throughput, low volume methods using SUPR-DSF instrument.
• RIC groupminorStrategic or Co-development PartnerEuropean centre of excellence in analytics. Worked with mAbsolve to characterize binding of Fc variants to receptors using sensitive chromatographic technique. Published comprehensive silencing analysis together.
• BioescalatorminorStrategic or Co-development PartnerOxford's medical research district providing lab space and support for high growth startups. Home to world-class institutes with 8500 staff and students.
• Abwiz BiominorChannel Partner/ Reseller/ DistributorUses proprietary phage library platforms and vectors for custom antibody services including affinity maturation, humanization, and discovery of unique rabbit antibodies.
• Impact IPcoreImplementation/ SI/ Consulting PartnerIntellectual property specialists in medical and life sciences. Assisted mAbsolve to obtain broad patent coverage for STR technology and structured agreements with licensees.
• EpivaxminorStrategic or Co-development PartnerPioneered immunogenicity risk assessment with in silico analysis and in vitro approaches. Their proprietary algorithms confirmed that STR mutations are unlikely to pose any risk of increased immunogenicity.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Xencor: Xencor engineers Fc domains (e.g., XmAb platforms) for therapeutic antibodies and licenses them to pharma/biotech, the closest direct analog to mAbsolve's STR licensing model in Fc engineering.
• Adimab: Adimab licenses antibody discovery and engineering platforms to pharma/biotech, mirroring mAbsolve's non-exclusive platform-licensing model in the broader antibody engineering value chain.

Regional players

• Absolute Antibody: Absolute Antibody is mAbsolve's parent/spin-out entity offering custom antibody engineering services and Fc-modified reagents; it is a close sibling rather than competitor but operates the same adjacent antibody engineering market.

Emerging players

• Crescendo Biologics: UK-based Crescendo develops Fc-engineered T cell engagers and biologics, overlapping with mAbsolve's Fc engineering focus on a smaller, more focused footprint.
• Inhibrx: Inhibrx engineers single-domain antibodies and Fc-containing fusion proteins, representing an emerging player with overlapping antibody engineering capabilities relevant to mAbsolve's customer base.

Broad incumbents

• MacroGenics: MacroGenics uses Fc-engineered antibodies (e.g., Fc-optimized, DuoBody bispecifics) in its clinical pipeline, representing a larger incumbent applying Fc modification to therapeutic antibodies.
• Argenx: Argenx develops antibody therapeutics (efgartigimod) leveraging Fc engineering/FcRn biology, validating the commercial opportunity for engineered Fc antibodies and serving as a broad incumbent in mAbsolve's application space.
• Ligand Pharmaceuticals: Ligand owns the OmniAb antibody discovery platform and licenses platform technologies to drug developers, operating a similar platform-licensing model at much larger scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about mAbsolve